Pancreatic CancerPhase 1/2NCT07444541
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
A Phase 1/2 study testing ANO31905, AG [gemcitabine+nab-paclitaxel] and mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] in people with Pancreatic Cancer, run by Anova Innovation Limited at 3 sites in United States.
Trial summary
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- ANO31905, AG [gemcitabine+nab-paclitaxel] and mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 3 sitesUnited States
- Study dates
- Dec 2026to Dec 2028
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients voluntarily participate in the study and sign the written ICF;
- Males or females aged ≥ 18 at the time of signing the ICF;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Expected survival ≥ 3 months;
- Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (including adenosquamous cell carcinoma) which is locally advanced unresectable or metastatic with the first diagnosis within 3 months before the first dose (clinical staging criteria are based on AJCC 8th edition);
- Those who have not received any anti-tumor treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, including but not limited to surgery, radiotherapy, and chemotherapy; however, if they have received palliative radiotherapy for metastases to bone and/or pain ≥14 days before the first dose of the study treatment and have recovered from all acute toxicities, they can be included. For previous systemic therapy in the neoadjuvant and/or adjuvant stage, the time of disease recurrence or progression must be ≥ 6 months after the last dose and within 3 months before the first study dose;
Show all 10Show fewer
- At least one measurable lesion according to RECIST v1.1;
- Tumor tissue samples are determined to be CLDN18.2-positive by immunohistochemistry (IHC) in the central laboratory, defined as ≥1% of tumor cells with membranous staining intensity ≥1+ determined by IHC;
- Patients with sufficient organ function within 7 days before the first study dose;
- Non-pregnant or -lactating women; patients of childbearing potential (male and female) must agree to use a reliable method of contraception with their partner from the signing of the ICF until at least 3 months for Cohort A or 6 months for Cohort B (for males) or 6 months for Cohort A or 9 months for Cohort B (for females) after the last dose; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first study dose.
Who cannot join
- Patients with other malignant tumors except pancreatic adenocarcinoma within 5 years before the first dose of the study treatment (except for in situ cancer of the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast);
- Patients who have previously received an organ transplant/allogeneic bone marrow transplant or are awaiting an organ transplant/allogeneic bone marrow transplant during the expected study period;
- Patients who have received treatment with herbal medicines with well documented anti-tumor effects or indications within 14 days before the first study dose;
- Patients who have participated in other interventional clinical trials and used interventional measures (such as drugs or devices) within 28 days before the first study dose;
- Patients who have undergone major organ surgery (excluding aspiration biopsy and venous catheterization) or experienced significant trauma within 28 days before the first study dose;
- Patients who have received attenuated live vaccines within 28 days before the first study dose or are expected to receive attenuated live vaccines during study treatment;
Show all 24Show fewer
- Patients with toxic reactions to previous anti-tumor therapy which haven't recovered to Grade ≤ 1 according to NCI-CTCAE v6.0 criteria (for CRS and ICANS, Grade ≤ 1 as per the ASTCT)),) excluding alopecia (any grade) or other toxic reactions with no safety risk considered by the investigator;
- Patients who have previously received treatment targeting CLDN18.2, including but not limited to monoclonal antibodies, bispecific antibodies, chimeric antigen receptor T-cell immunotherapy (CAR-T), or antibody-drug conjugate (ADC);
- Patients who have received corticosteroids for systemic use (> 10 mg/day prednisone or equivalent) or other immunosuppressants (including but not limited to cyclophosphamide, methotrexate, and thalidomide) within 14 days before the first study dose or expected to receive during study treatment, except that substitution therapy with physiological doses of corticosteroids (ie, ≤ 10 mg/day prednisone or equivalent) is allowed for insufficiency adrenal cortex in the absence of active autoimmune disorders, topical, ocular, intra-articular, intranasal and inhalation use of glucocorticoids are allowed, and the use of glucocorticoids to prevent contrast media allergy is allowed;
- Patients with a history of active autoimmune disorders or autoimmune disorders requiring systemic treatment;
- Patients who have previously experienced serious adverse reactions related to immunotherapy, or intolerance to immunotherapy;
- Patients with known hypersensitivity to any component or excipient of ANO31905, gemcitabine, and nanoparticle albumin-bound paclitaxel;
- For Cohort B, use of strong inhibitors or inducers of CYP3A or use of strong inhibitors of UGT1A1.
- For Cohort B, known low or absent dihydropyrimidine dehydrogenase (DPD) activity. Where required by local regulations, testing for DPD deficiency must be performed using a validated method which is recommended by local health authorities.
- Patients with known metastases to the central nervous system;
- Patients with a poor nutrition condition of indicated by a weight ≤40 kg or body mass index (BMI) <18.0 kg/m2; if symptomatic nutritional support is provided and the condition is corrected before the first study dose, continued screening for enrollment may be considered after assessment by the investigator;
- Patients a with serious systemic infection or a medically unexplained fever ≥ 38.5°C (101.3°F) within 28 days before the first study dose;
- Patients with severe cardiovascular and cardiovascular diseases;
- Presence risks of thrombosis or bleeding:
- Patients having severe advanced diseases with comorbidities that may be life-threatening in the short term;
- Patients with gastrointestinal diseases that are not suitable for enrollment as judged by the investigator;
- Patients with known or suspected interstitial pneumonitis, moderate to severe lung diseases that seriously affect respiratory function
- Patients with hepatitis B, hepatitis C, or a known HIV positive history or positive HIV screening;
- Patients with other conditions that may place the patients at increased undue study-related risks.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Recruiting
Site 01002
Los Angeles, California, 90027
Ghassan Al-Jazayrly, 323-660-6200, pi@caresinst.com
- Recruiting
Site 01009
Plantation, Florida, 33322
Andrew Schneider, 561-447-0614, aschneider.md@brcrglobal.com
- Recruiting
Site 01005
San Antonio, Texas, 78229
Drew Raso, 210-593-5259, drew.rasco@startresearch.com
About this study
Official title: A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer
- Being tested
- ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ANO31905Drug
ANO31905 will be administered as an IV infusion
AG [gemcitabine+nab-paclitaxel]Drug
125 mg/m^2 of nab-paclitaxel, intravenous infusion, D1/D8/D15 per cycle; 1000 mg/m^2 of gemcitabine, intravenous infusion, D1/D8/D15 per cycle until PD, intolerable toxicity or other discontinuation criteria specified in the protocol (whichever occurs first).
mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]Drug
Oxaliplatin, 85 mg/m^2; irinotecan (non-liposome injection), 180 mg/m^2; leucovorin, 400 mg/m^2; and fluorouracil, 2400 mg/m^2 given as a 46-hour continuous infusion, on D1/D15 per cycle.
| Study group | Role | What they receive |
|---|---|---|
| ANO31905+AG | Experimental | Not described Receives: Drug: ANO31905; Drug: AG [gemcitabine+nab-paclitaxel] |
| ANO31905+mFOLFIRINOX | Experimental | Not described Receives: Drug: ANO31905; Drug: mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose-limiting toxicity (DLT) (Phase Ib).
The severity of adverse events (AEs) will be graded according to the Common Terminology Criteria for Adverse Events Version 6.0. AEs that occur during the DLT observation period and are judged to be "definitely related", "probably related", or "possibly related" to any investigational products will be deemed as a DLT event.
Measured: At the end of Cycle 1 (each cycle is 28 days)
Objective response rate (ORR) assessed by the investigator according to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1) (Phase Ⅱ)
Objective response rate (ORR) is defined as the proportion of patients with the best efficacy evaluation of complete response (CR) or partial response (PR) during the study. From date of treatment start until disease progression, date of death or withdrawal from study, whichever came first.
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study startDec 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Anova Innovation Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07444541
- Sponsor's protocol ID
- ANO31905-204
- Status last verified
- Oct 2026
- First submitted
- 9 Feb 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No